Cizzle Biotechnology Holdings Plc, together with its subsidiaries, operates as a cancer diagnostics company in the United Kingdom. It develops a non-invasive blood immunoassay test for early lung cancer detection using CIZ1B biomarker technology. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.…
Cizzle Bio Expands CIZ1B Lung Cancer Testing Into San Antonio
Cizzle Biotechnology Raises £500,000 To Support US Lung Cancer Test Adoption
Cizzle Biotechnology Holdings (LON: CIZ) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 5 employees.
The shares were at 1.025 GBp on 20 November 2026, down 37.9% over 52 weeks. Its 52-week range is 0.9000 GBp to 3.900 GBp: the price is 73.7% below the high and 13.9% above the low.
Its market capitalisation is 4.92M GBP.
Cizzle Biotechnology Holdings reports return on equity of 203.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 81.00K GBP. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.
No upcoming events tracked.